European Journal of Cancer
Volume 45, Issue 17 , Pages 2928-2929 , November 2009

Management of aggressive fibromatosis: Can we unravel the maze of treatment options?

Received 7 September 2009 ,Accepted 10 September 2009.

References 

  1. De Bree E, Keus R, Melissas J, et al. Desmoid tumors: need for an individualized approach. Expert Rev Anticancer Ther. 2009;9:525–535
  2. Fiore M, Rimareix F, Mariani L, et al. Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment. Ann Surg Oncol. 2009;16:2587–2593
  3. Janinis J, Patriki M, Vini L, et al. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol. 2003;14:181–190
  4. Gega M, Yanagi H, Yoshikawa R, et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol. 2006;24:102–105
  5. Dufresne A, Penel N, Salas S, et al. Updated outcome with long-term follow-up of imatinib for the treatment of progressive or recurrent aggressive fibromatosis (desmoid tumor): a FNCLCC/French Sarcoma Group phase II trial. J Clin Oncol. 2009;27:15s;[Suppl.; abstr. 10518]
  6. Constantinidou A, Jones RL, Scurr M, et al. Pegylated liposomal doxorubicin, an effective, well tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer, this issue.
  7. Lazar AJ, Tuvin D, Hajibashi S, et al. Specific mutation in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoids tumors. Am J Pathol. 2008;173:1518–1527

PII: S0959-8049(09)00698-4

doi: 10.1016/j.ejca.2009.09.012

European Journal of Cancer
Volume 45, Issue 17 , Pages 2928-2929 , November 2009

Article Tools